In the last trading session, 1.3 million shares of the AbCellera Biologics Inc (NASDAQ:ABCL) were traded, and its beta was 0.36. Most recently the company’s share price was $2.57, and it changed around -$0.06 or -2.28% from the last close, which brings the market valuation of the company to $757.30M. ABCL currently trades at a discount to its 52-week high of $6.05, offering almost -135.41% off that amount. The share price’s 52-week low was $2.34, which indicates that the current value has risen by an impressive 8.95% since then. We note from AbCellera Biologics Inc’s average daily trading volume that its 10-day average is 1.48 million shares, with the 3-month average coming to 1.80 million.

AbCellera Biologics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.22. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended ABCL as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. AbCellera Biologics Inc is expected to report earnings per share of -0.15 for the current quarter.

AbCellera Biologics Inc (NASDAQ:ABCL) trade information

Instantly ABCL has showed a red trend with a performance of -2.28% at the end of last trading. The rise to weekly highs of 2.63 on recent trading dayincreased the stock’s daily price by 2.28%. On the other hand, AbCellera Biologics Inc (NASDAQ:ABCL) is 7.08% up in the 30-day period. We can see from the shorts that 16.84 million shares have been sold at a short interest cover period of 7.86 day(s).

The consensus price target as assigned by Wall Street analysts is $29, which translates to bulls needing to increase their stock price by 91.14% from its current value. Analyst projections state that ABCL is forecast to be at a low of $5 and a high of $34.

AbCellera Biologics Inc (ABCL) estimates and forecasts

AbCellera Biologics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -45.67 percent over the past six months and at a -7.84% annual growth rate that is well below the industry average of 17.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -50.00% in revenue this quarter, and will report an increase of 5.90% in the next quarter. The year-over-year growth rate is expected to be -11.60%, down from the previous year.

Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 7.95M in revenue for the current quarter. 8 analysts expect AbCellera Biologics Inc to make 8.24M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 11.84M and 9.18M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -32.90%. Forecasts for the next quarter put sales growth at -10.20%.

AbCellera Biologics Inc earnings are expected to increase by 10.68% in 2024, but the outlook is positive 10.00% per year for the next five years.

ABCL Dividends

AbCellera Biologics Inc’s next quarterly earnings report is expected to be released in November.

AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 28.05% of AbCellera Biologics Inc shares, and 42.22% of them are in the hands of institutional investors. The stock currently has a share float of 58.69%. AbCellera Biologics Inc stock is held by 211.0 institutions, with BAKER BROS. ADVISORS LP being the largest institutional investor. By 2024-06-30, it held 9.4033% of the shares, which is about 27.53 million shares worth $81.48 million.

BAILLIE GIFFORD & CO, with 7.4852% or 21.91 million shares worth $64.86 million as of 2024-06-30, holds the second largest percentage of outstanding shares.